Skip to main content Accessibility help
×
Home
  • Print publication year: 2012
  • Online publication date: August 2012

2 - Evidence-based pharmacotherapy of schizophrenia

References

Adams CE, Coutinho E, Davis JM et al. (2008). Cochrane Schizophrenia Group. The Cochrane Library. Chichester: John Wiley & Sons.
Adams CE, Fenton MKP, Quraishi S, David AS (2000). Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 179, 190–199.
Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action – a hypothesis tested and rejected. Archives of General Psychiatry 60, 1228–1235.
Agid O, Kapur S, Warrington L et al. (2008). Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophrenia Research 102, 241–248.
Akhondzadeh S, Tabatbaee M, Amini H et al. (2007). Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophrenia Research 90, 179–185.
Aleman A, Sommer IE, Kahn RS (2007). Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. Journal of Clinical Psychiatry 68, 416–421.
Alexander J, Tharyan P, Adams C et al. (2004). Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting – pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. British Journal of Psychiatry 185, 63–69.
Allison DB, Mentore JL, Heo M et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156, 1686–1696.
Altamura AC, Velona I, Curreli R et al. (2002). Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial responders. International Journal of Psychiatry in Clinical Practice 6, 107–111.
Alvir JMJ (1994). Agranulocytosis: incidence and risk factors. Journal of Clinical Psychiatry 55, 137–138.
Andreasen NC, Pressler M, Nopoulos P et al. (2010). Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry 67, 255–262.
Arato M, O’Connor R, Meltzer H, Zeus Study Group (2002). Ziprasidone in the long-term treatment of negative symptoms and the prevention of exacerbation of schizophrenia. International Clinical Psychopharmacology 17, 207–215.
Ascher-Svanum H, Nyhuis AW, Faries DE et al. (2008). Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophrenia Bulletin 34, 1163–1171.
Baldessarini RJ, Cohen BM, Teicher MH (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 45, 79–91.
Barbui C, Saraceno B, Liberati A, Garattini S (1996). Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials. European Psychiatry 11, 306–311.
Barbui C, Signoretti A, Mule S et al. (2009). Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophrenia Bulletin 35, 458–468.
Barnes TR, McPhillips MA (1995). How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. International Clinical Psychopharmacology 10 (Suppl. 3), 115–121.
Basan A, Kissling W, Leucht S (2004). Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophrenia Research 70, 33–37.
Battaglia J, Moss S, Rush J et al. (1997). Haloperidol, lorazepam, or both for psychotic agitation: a multicenter, prospective, double blind, emergency department study. American Journal of Emergency Medicine 15, 335–340.
Baumann P, Hiemke C, Ulrich S et al. (2004). The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37, 243–265.
Bollini P (1994). Antipsychotic drugs: is more worse? A meta analysis of the published randomized controlled trials. Psychological Medicine 24, 307–316.
Breier A, Hamilton SH (1999). Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biological Psychiatry 45, 403–411.
Buchanan RW, Ball MP, Weiner E et al. (2005). Olanzapine treatment of residual positive and negative symptoms. American Journal of Psychiatry 162, 124–129.
Buchanan RW, Kreyenbuhl J, Kelly DL et al. (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 36, 71–93.
Bushe C, Shaw M, Peveler RC (2008). A review of the association between antipsychotic use and hyperprolactinaemia. Journal of Psychopharmacology 22, 46–55.
Carpenter WT, Hanlon TE, Heinrichs DW et al. (1990). Continuous vs. targeted medication in schizophrenic outpatients: outcome results. American Journal of Psychiatry 147, 1138–1163.
Casey DE, Daniel DG, Tamminga C et al. (2009). Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 34, 1330–1338.
Casey DE, Daniel DG, Wassef AA et al. (2003). Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28, 182–192.
Chakos M, Lieberman J, Hoffman E et al. (2001). Effectiveness of second generation antipsychotics for treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158, 518–526.
Chang JS, Ahn YM, Park HJ et al. (2008). Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 69, 720–731.
Chang YC, Lane HY, Yang KH, Huang CL (2006). Optimizing early prediction for antipsychotic response in schizophrenia. Journal of Clinical Psychopharmacology 26, 554–559.
Cheine M, Ahonen J, Wahlbeck K (2001). Beta-blocker supplementation of standard drug treatment for schizophrenia. Cochrane Database of Systematic Reviews 3, CD000234.
Chen EYH, Hui CLM, Lam MML et al. (2010). Maintenance treatment with quetiapine vs. discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. British Medical Journal 341, c4024.
Cheung HK (1981). Schizophrenics fully remitted on neuroleptics for 3–5 years – to stop or continue drugs? British Journal of Psychiatry 138, 490–494.
Chua WL, Santiago AD, Kulkarni J, Mortimer A (2005). Estrogen for schizophrenia. Cochrane Database of Systematic Reviews 4, CD004719.
Citrome L (2007). Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. Journal of Clinical Psychiatry 68, 1876–1885.
Conley RR, Kelly DL, Nelson MW et al. (2005). Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clinical Neuropharmacology 28, 163–168.
Conley RR, Tamminga CA, Bartko JJ et al. (1998). Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. American Journal of Psychiatry 155, 914–920.
Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies. American Journal of Psychiatry 161, 414–415.
Correll CU, Malhotra AK, Kaushik S et al. (2003). Early prediction of antipsychotic response in schizophrenia. American Journal of Psychiatry 160, 2063–2065.
Correll CU, Rummel-Kluge C, Corves C et al. (2009). Antipsychotic combinations vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 35, 443–457.
Correll CU, Schenk EM (2008). Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry 21, 151–156.
Crow TJ, MacMillan JF, Johnson AL, Johnstone EC (1986). A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 148, 120–127.
Davis JM (1974). Dose equivalence of the antipsychotic drugs. Journal of Psychiatric Research 11, 65–69.
Davis JM, Chen N (2004). Dose-response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology 24, 192–208.
Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60, 553–564.
De Hert M, Dekker JM, Wood D et al. (2009). Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry 24, 412–424.
Ehrenreich H, Hinze-Selch D, Stawicki S et al. (2007). Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Molecular Psychiatry 12, 206–220.
Elias A, Kumar A (2007). Testosterone for schizophrenia. Cochrane Database of Systematic Reviews 3, CD006197.
Emsley RA, Raniwalla J, Bailey PJ, Jones AM (2000). A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. International Clinical Psychopharmacology 15, 121–131.
Essali A, Al-Haj HN, Li C, Rathbone J (2009). Clozapine vs. typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 1, CD000059.
Falkai P, Wobrock T, Lieberman J et al. (2005). World Federation of Societies of Biological Psychiatry (WFSBP) – Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry 6, 132–191.
Fleischhacker WW, Heikkinen ME, Olie JP et al. (2008). Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. European Psychiatry 23, S114–S115.
Gaebel W, Awad AG (1994). Prediction of Neuroleptic Treatment Outcome in Schizophrenia. Concepts and Methods. Vienna: Springer Verlag.
Gaebel W, Falkai P, Weinmann S, Wobrock T (2006). Behandlungsleitlinie Schizophrenic. Darmstadt: Steinkopff.
Gaebel W, Riesbeck M, Wölwer W et al. (2010). Relapse prevention in first episode schizophrenia. Maintenance vs. intermittent drug treatment with a prodrome based early intervention: Results of a randomised controlled trial within the German research network on schizophrenia. Journal of Clinical Psychiatry. Published online: 29 June 2010. doi:10.4088/JCP.09m05459yel.
Gaebel W, Weinmann S, Sartorius N et al. (2005). Schizophrenia practice guidelines: international survey and comparison. British Journal of Psychiatry 187, 248–255.
Gardner DM, Murphy AL, O’Donnell H et al. (2010). International consensus study of antipsychotic dosing. American Journal of Psychiatry 167, 686–693.
Geddes J, Freemantle N, Harrison P, Bebbington P (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321, 1371–1376.
Gilbert P, Harris J, McAdams LA, Jeste DV (1995). Neuroleptic withdrawal in schizophrenia. Review of the literature. Archives of General Psychiatry 52, 173–188.
Goodwin G, Fleischhacker W, Arango C et al. (2009). Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. European Neuropsychopharmacology 19, 520–532.
Hajak G, Marienhagen J, Langguth B et al. (2004). High-frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study. Psychological Medicine 34, 1157–1163.
Hamann J, Leucht S, Kissling W (2003). Shared decision making in psychiatry. Acta Psychiatrica Scandinavica 107, 403–409.
Hartung B, Wada M, Laux G, Leucht S (2005). Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews 1, CD003443.
Herz MI, Glazer WM, Mostert MA et al. (1991). Intermittent vs. maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry 48, 333–339.
Hogarty GE, McEvoy JP (1988). Dose of fluphenazine, familial expressed emotions and outcome in schizophrenia. Archives of General Psychiatry 45, 797–805.
Hogarty GE, Ulrich RF (1998). The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. Journal of Psychiatric Research 32, 243–250.
Hogarty GE, Ulrich RF, Mussare F, Aristigueta N (1976). Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Diseases of the Nervous System 37, 494–500.
Hoyberg OJ, Fensbo C (1993). Risperidone vs. perphenazine in the treatment of chronic schizophrenic patients with acute exacerbation. Acta Psychiatrica Scandinavica 88, 396–402.
Huf G, Coutinho ES, Adams CE (2007). Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol vs. intramuscular haloperidol plus promethazine. British Medical Journal 335, 869.
Huf G, Coutinho ESF, Adams CE et al. (2003). Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam vs. haloperidol plus promethazine. British Medical Journal 327, 708–711.
Jager M, Schmauss M, Laux G et al. (2009). Early improvement as a predictor of remission and response in schizophrenia: results from a naturalistic study 3. European Psychiatry 24, 501–506.
Jeste DV, Lacro JP, Gilbert PL et al. (1993). Treatment of late-life schizophrenia with neuroleptics. Schizophrenia Bulletin 19, 817–830.
Johnson DA (1976). The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatrica Scandinavica 53, 298–301.
Johnson DA, Ludlow JM, Street K, Taylor RD (1987). Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry 151, 634–638.
Johnson DAW (1979). Further observation on the duration of depot neuroleptic maintenance therapy in schizophrenia. British Journal of Psychiatry 135, 524–530.
Jolley AG, Hirsch SR (1990). Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. British Medical Journal 301, 837–842.
Jones PB, Barnes TRE, Davies L et al. (2006). Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia – cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 63, 1079–1086.
Joy CB, Mumby-Croft R, Joy LA (2006). Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews 3, CD001257.
Kahn RS, Fleischhacker WW, Boter H et al. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085–1097.
Kane JM (1982). Fluphenazine vs. placebo in patients with remitted, acute first-episode schizophrenia. Archives of General Psychiatry 39, 70–73.
Kane JM, Correll CU, Goff DC et al. (2009). A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. Journal of Clinical Psychiatry 70, 1348–1357.
Kane JM, Davis JM, Schooler N et al. (2002). A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. American Journal of Psychiatry 159, 554–560.
Kane JM, Honigfeld G, Singer J et al. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789–796.
Kane JM, Khanna S, Rajadhyaksha S, Giller E (2006). Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. International Clinical Psychopharmacology 21, 21–28.
Kane JM, Leucht S, Carpenter D, Docherty JP (2003). Optimising pharmacologic treatment of psychotic disorders. Journal of Clinical Psychiatry 64 (Suppl. 12), 1–100.
Kane JM, Marder SR, Schooler NR et al. (2001). Clozapine and haloperidol in moderately refractory schizophrenia – a 6-month randomized and double-blind comparison. Archives of General Psychiatry 58, 965–972.
Kane JM, Meltzer HY, Carson WH et al. (2007). Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study vs. perphenazine. Journal of Clinical Psychiatry 68, 213–223.
Kane JM, Rifkin A, Woerner M et al. (1983). Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry 40, 893–896.
Kapur S, Arenovich T, Agid O et al. (2005). Evidence for onset of antipsychotic effects within the first 24 h of treatment. American Journal of Psychiatry 162, 939–946.
Kinon BJ, Chen L, Ascher-Svanum H et al. (2008a). Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 102, 230–240.
Kinon BJ, Chen L, Ascher-Svanum H et al. (2010). Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35, 581–590.
Kinon BJ, Kane JM, Johns C et al. (1993). Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacology Bulletin 29, 309–314.
Kinon BJ, Volavka J, Stauffer V et al. (2008b). Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. Journal of Clinical Psychopharmacology 28, 392–400.
Kissling W, Kane JM, Barnes TR et al. (1991). Guidelines for neuroleptic relapse prevention in schizophrenia: towards consensus view. In Kissling W (Ed.), Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (pp. 155–163). Heidelberg: Springer.
Klein DF, Davis JM (1969). Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, MD: Williams and Wilkins.
Klein E, Kolsky Y, Puyerovsky M et al. (1999). Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double-blind sham-controlled pilot study. Biological Psychiatry 46, 1451–1454.
Kleinberg DL, Davis JM, de Coster R et al. (1999). Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacology 19, 57–61.
Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB (2006). Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 63, 622–629.
Lambert M, Schimmelmann BG, Naber D, Eich FX et al. (2009). Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry 42, 277–283.
Lehman AF, Lieberman JA, Dixon LB et al. (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161, 1–56.
Leucht C, Heres S, Kane JM et al. (2011). Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research 127, 83–92.
Leucht C, Kitzmantel M, Chua L et al. (2008 a). Haloperidol vs. chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 1, CD004278.
Leucht S, Arbter D, Engel RR et al. (2008 b). How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry. Published online: 8 January 2008. doi:10.1038/sj.mp .4002136.
Leucht S, Barnes TRE, Kissling W et al. (2003 a). Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry 160, 1209–1222.
Leucht S, Busch R, Hamann J et al. (2005 a). Early onset of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry 57, 1543–1549.
Leucht S, Busch R, Kissling W, Kane JM (2007a). Early prediction of antipsychotic non-response. Journal of Clinical Psychiatry 68, 352–360.
Leucht S, Corves C, Arbter D et al. (2009 a). Second-generation vs. first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31–41.
Leucht S, Heres S (2006). Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. Journal of Clinical Psychiatry 67, 3–8.
Leucht S, Kane JM, Etschel E et al. (2006). Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31, 2318–2325.
Leucht S, Kane JM, Kissling W et al. (2005 b). Clinical implications of BPRS scores. British Journal of Psychiatry 187, 363–371.
Leucht S, Kane JM, Kissling W et al. (2005 c). What does the PANSS mean? Schizophrenia Research 79, 231–238.
Leucht S, Kissling W, McGrath J (2007 b). Lithium for schizophrenia. Cochrane Database of Systematic Reviews 3, CD003834.
Leucht S, Komossa K, Rummel-Kluge C et al. (2009 b). A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 166, 152–163.
Leucht S, McGrath J, White P, Kissling W (2002 a). Carbamazepine augmentation for schizophrenia: how good is the evidence? Journal of Clinical Psychiatry 63, 218–224.
Leucht S, Pitschel-Walz G, Engel R, Kissling W (2002 b). Amisulpride – an unusual atypical antipsychotic. A meta-analysis of randomized controlled trials. American Journal of Psychiatry 159, 180–190.
Leucht S, Shamsi AS, Busch R et al. (2008 c). Early prediction of antipsychotic response – replication and six weeks extension. Schizophrenia Research 101, 312–319.
Leucht S, Wahlbeck K, Hamann J, Kissling W (2003 b). New generation antipsychotics vs. low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361, 1581–1589.
Levine SZ, Leucht S (2010). Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biological Psychiatry 68, 86–92.
Levine SZ, Rabinowitz J (2010). Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophrenia Bulletin 36, 624–632.
Lewis SW, Barnes TR, Davies L et al. (2006). Randomized controlled trial of effect of prescription of clozapine vs. other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32, 715–723.
Lieberman JA (1998). Maximizing clozapine therapy: managing side effects. Journal of Clinical Psychiatry 59, 38–43.
Lieberman JA, Stroup TS, McEvoy JP et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209–1223.
Lin CH, Chou LS, Lin CH et al. (2007). Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. Journal of Clinical Psychiatry 68, 1522–1527.
Lindenmayer JP, Khan A, Iskander A et al. (2007). A randomized controlled trial of olanzapine vs. haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. Journal of Clinical Psychiatry 68, 368–379.
Marder SR, Vanputten T, Mintz J et al. (1984). Costs and benefits of 2 doses of fluphenazine. Archives of General Psychiatry 41, 1025–1029.
McEvoy JP, Hogarty GE, Steingard S (1991). Optimal dose of neuroleptic in acute schizophrenia. Archives of General Psychiatry 48, 740–745.
McEvoy JP, Lieberman JA, Stroup TS et al. (2006). Effectiveness of clozapine vs. olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163, 600–610.
McGorry PD (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 39, 1–30.
Moller HJ, Kissling W, Lang C et al. (1982). Efficacy and side effects of haloperidol in psychotic patients: oral vs. intravenous administration. American Journal of Psychiatry 139, 1571–1575.
Muller N, Riedel M, Scheppach C et al. (2002). Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry 159, 1029–1034.
Naber D, Hippius H (1990). The European experience with use of clozapine. Hospital and Community Psychiatry 41, 886–890.
NICE (2003). Schizophrenia: Full National Guideline on Core Interventions in Primary and Secondary Care. London: National Institute for Clinical Excellence/Royal College of Psychiatrists.
Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects – a comprehensive literature review. CNS Drugs 19, 1–93.
Nolte S, Wong D, Latchford G (2004). Amphetamines for schizophrenia. Cochrane Database of Systematic Reviews 4, CD004964.
Odejide OA, Aderounmu AF (1982). Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry 43, 195–196.
Omori IM, Wang J (2009). Sulpiride vs. placebo for schizophrenia. Cochrane Database of Systematic Reviews 2, CD007811.
Patel MX, Taylor M, David AS (2009). Antipsychotic long-acting injections: mind the gap. British Journal of Psychiatry (Suppl.) 52, S1–S4.
Paton C, Whittington C, Barnes TR (2007). Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine – a meta-analysis. Journal of Clinical Psychopharmacology 27, 198–204.
Pietzcker A, Gaebel W, Koepcke W et al. (1993). Intermittent vs. maintenance neuroleptic long-term treatment in schizophrenia – 2 years’ results of a German multicenter study. Journal of Psychiatric Research 27, 321–339.
Premkumar TS, Pick J (2006). Lamotrigine for schizophrenia. Cochrane Database of Systematic Reviews 4, CD005962.
Raveendran NS, Tharyan P, Alexander J, Adams CE (2007). Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine vs. intramuscular haloperidol plus promethazine. British Medical Journal 335, 865.
Robinson D, Woerner MG, Alvir JM et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 56, 241–247.
Rosenheck R, Cramer J, Xu WC et al. (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 337, 809–815.
Rosenheck R, Perlick D, Bingham S et al. (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia – a randomized controlled trial. Journal of the American Medical Association 290, 2693–2702.
Rummel C, Kissling W, Leucht S (2006). Antidepressants for the negative symptoms of schizophrenia. Cochrane Database of Systematic Reviews 3, CD005581.
Rummel-Kluge C, Komossa K, Schwarz S et al. (2010). Second generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophrenia Bulletin. Published online: 31 May 2010. doi:10.1093/schbul/sbq042.
Sampath G, Shah A, Krska J, Soni SD (1992). Neuroleptic discontinuation in the very stable schizophrenic patient – relapse rates and serum neuroleptic levels. Human Psychopharmacology: Clinical and Experimental 7, 255–264.
Schooler NR, Keith SJ, Severe JB et al. (1997). Relapse and rehospitalization during maintenance treatment of schizophrenia. Archives of General Psychiatry 54, 453–463.
See RE, Fido AA, Maurice M et al. (1999). Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biological Psychiatry 45, 1653–1656.
Sepehry AA, Potvin S, Elie R, Stip E (2007). Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. Journal of Clinical Psychiatry 68, 604–610.
Shalev A, Hermesh H, Rothberg J, Munitz H (1993). Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica 87, 86–91.
Shepherd M, Watt D, Falloon I, Smeeton N (1989). The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine (Suppl.) 15, 1–46.
Simpson GM, Mahmoud RA, Lasser RA et al. (2006). A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 67, 1194–1203.
Singh SP, Singh V, Kar N, Chan K (2010). Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. British Journal of Psychiatry 197, 174–179.
Siris SG (1991). Diagnosis of secondary depression in schizophrenia: implications for DSM–IV. Schizophrenia Bulletin 17, 75–98.
Smith RC, Infante M, Singh A, Khandat A (2001). The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. International Journal of Neuropsychopharmacology 4, 239–250.
Stip E, Sepehry AA, Chouinard S (2007). Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2. Clinical Neuropharmacology 30, 218–229.
Stone JM, Raffin M, Morrison P, McGuire PK (2010). The biological basis of antipsychotic response in schizophrenia. Journal of Psychopharmacology 24, 953–964.
Stroup TS, Lieberman JA, McEvoy JP et al. (2007). Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. American Journal of Psychiatry 164, 415–427.
Suzuki T, Uchida H, Watanabe K et al. (2007). How effective is it to sequentially switch among olanzapine, quetiapine and risperidone? – A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berlin) 195, 285–295.
Taylor DM, Smith L (2009). Augmentation of clozapine with a second antipsychotic – a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatrica Scandinavica 119, 419–425.
Tharyan P, Adams CE (2005). Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2, CD000076.
Tiihonen J, Wahlbeck K, Kiviniemi V (2009). The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 109, 10–14.
Tollefson GD, Beasley CM, Tran PV et al. (1997). Olanzapine vs. haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 154, 457–465.
Tranulis C, Sepehry AA, Galinowski A, Stip E (2008). Should we treat auditory hallucinations with repetitive transcranial magnetic stimulation? A meta-analysis. Canadian Journal of Psychiatry 53, 577–586.
Trikalinos TA, Churchill R, Ferri M et al. (2004). Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology 57, 1124–1130.
Tuominen HJ, Tiihonen J, Wahlbeck K (2006). Glutamatergic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2, CD003730.
Uchida H, Suzuki T, Takeuchi H et al. (2009). Low dose vs. standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophrenia Bulletin. Published online: 27 November 2009. doi :10.1093/schbul/sbpl49.
Volavka J, Czobor P, Sheitman B et al. (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry 159, 255–262.
Volz A, Khorsand V, Gillies D, Leucht S (2007). Benzodiazepines for Schizophrenia. Cochrane Library. Chichester: John Wiley & Sons.
Wahlbeck K, Cheine M, Essali A, Adams C (1999). Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. American Journal of Psychiatry 156, 990–999.
Wang CY, Xiang YT, Cai ZJ et al. (2010). Risperidone maintenance treatment in schizophrenia. A randomised, controlled trial. American Journal of Psychiatry 167, 676–685.
Waraich P, Adams C, Hammill K et al. (2002). Haloperidol dose for the acutely ill phase of schizophrenia. Cochrane Database of Systematic Reviews 2, CD001951.
Whitehead C, Moss S, Cardno A, Lewis G (2003). Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychological Medicine 33, 589–599.
Wirshing DA, Marshall BD, Green MF et al. (1999). Risperidone in treatment-refractory schizophrenia. American Journal of Psychiatry 156, 1374–1379.
Wunderink L, Nienhuis FJ, Sytema S et al. (2007). Guided discontinuation vs. maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. Journal of Clinical Psychiatry 68, 654–661.
Zimbroff DL, Kane JM, Tamminga CA et al. (1997). Controlled, dose response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry 154, 782–791.